Tibet Weixinkang Medicine Co., Ltd. (SHA:603676)
China · Delayed Price · Currency is CNY 8.10
-0.14 (-1.70%)
Nov 13, 2026, 3:00 PM CST
Tibet Weixinkang Medicine Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 3,502 | 4,548 | 4,330 | 4,539 | 6,928 | 4,051 | |
Market Cap Growth | -30.17% | 5.04% | -4.60% | -34.48% | 71.03% | 6.52% |
Enterprise Value | 2,499 | 3,539 | 3,282 | 3,710 | 6,150 | 3,412 |
Last Close Price | 8.10 | 10.29 | 9.45 | 9.42 | 14.15 | 8.12 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 18.39 | 19.53 | 17.59 | 21.21 | 39.15 | 42.23 |
PS Ratio | 3.21 | 4.01 | 3.33 | 3.43 | 4.95 | 3.92 |
PB Ratio | 2.22 | 3.08 | 3.13 | 3.39 | 5.68 | 3.80 |
P/TBV Ratio | 2.25 | 3.13 | 3.16 | 3.48 | 5.79 | 3.84 |
P/FCF Ratio | 26.94 | 44.76 | 13.76 | 26.65 | 41.12 | 35.20 |
P/OCF Ratio | 15.90 | 24.51 | 11.62 | 18.82 | 28.14 | 23.73 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 2.29 | 3.12 | 2.52 | 2.81 | 4.40 | 3.30 |
EV/EBITDA Ratio | 12.89 | 13.46 | 12.21 | 19.75 | 32.23 | 27.40 |
EV/EBIT Ratio | 17.55 | 16.11 | 14.75 | 25.58 | 39.80 | 36.72 |
EV/FCF Ratio | 19.22 | 34.83 | 10.43 | 21.79 | 36.51 | 29.64 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 | 0.01 |
Debt / EBITDA Ratio | 0.05 | 0.04 | 0.02 | 0.04 | 0.03 | 0.04 |
Debt / FCF Ratio | 0.07 | 0.11 | 0.02 | 0.05 | 0.03 | 0.04 |
Net Debt / Equity Ratio | -0.64 | -0.66 | -0.73 | -0.66 | -0.66 | -0.66 |
Net Debt / EBITDA Ratio | -5.48 | -3.69 | -3.77 | -4.72 | -4.20 | -5.67 |
Net Debt / FCF Ratio | -7.72 | -9.56 | -3.22 | -5.21 | -4.75 | -6.14 |
Asset Turnover | 0.56 | 0.61 | 0.72 | 0.77 | 0.89 | 0.72 |
Inventory Turnover | 8.49 | 8.69 | 15.05 | 18.37 | 24.34 | 22.67 |
Quick Ratio | 3.46 | 3.21 | 2.79 | 2.73 | 2.50 | 2.16 |
Current Ratio | 3.96 | 3.70 | 3.08 | 3.04 | 2.77 | 2.41 |
Return on Equity (ROE) | 12.27% | 16.27% | 18.06% | 16.71% | 15.47% | 9.35% |
Return on Assets (ROA) | 4.60% | 7.38% | 7.66% | 5.27% | 6.11% | 4.07% |
Return on Invested Capital (ROIC) | 23.04% | 41.15% | 48.02% | 32.94% | 38.42% | 20.31% |
Return on Capital Employed (ROCE) | 8.80% | 14.50% | 15.60% | 10.50% | 12.30% | 8.60% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 5.44% | 5.12% | 5.68% | 4.71% | 2.55% | 2.37% |
FCF Yield | 3.71% | 2.23% | 7.27% | 3.75% | 2.43% | 2.84% |
Dividend Yield | 4.04% | 3.11% | 3.42% | 2.73% | 1.48% | 1.72% |
Payout Ratio | 77.14% | 70.19% | 72.25% | 45.72% | 38.80% | 41.90% |
Buyback Yield / Dilution | -0.81% | 0.15% | -0.90% | 0.83% | -3.50% | 0.08% |
Total Shareholder Return | 3.23% | 3.26% | 2.52% | 3.56% | -2.02% | 1.80% |